Acne Procedural denied as not FDA-approved for this use by Humana?

Humana's specific coverage criteria for acne procedural are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denied Acne Procedural Treatment as Not FDA-Approved

For procedural acne treatments, a "not FDA-approved" denial typically targets a specific device (laser, light source, radiofrequency device) or a pharmacologic agent (such as a photosensitizer) used in the procedure that either lacks FDA clearance for the acne indication or is being used outside the scope of its cleared indication (off-label use). Understanding exactly which component was flagged — the device, the agent, or the specific indication — is critical before drafting your appeal.

## Why This Denial Is Appealable

Many acne procedural devices carry FDA 510(k) clearance for acne or acne-related indications. If the device your provider used is cleared, your appeal should document that clearance explicitly. If an agent is being used off-label, off-label use is a legal and common medical practice — Humana and other insurers are not permitted to categorically exclude coverage of off-label use when there is accepted medical evidence supporting efficacy. The AAD's clinical practice guidelines on acne management address procedural modalities and can anchor a medical-evidence argument.

## Federal Appeal Framework

• Internal appeal: File under ERISA §503 or ACA §2719 within the deadline on your denial letter. Attach documentation of FDA clearance status for the specific device or agent.
• External review: This is a clinical determination eligible for independent external review by an accredited IRO — not just an administrative correction. The window is up to four months from final internal denial. Expedited review is available when delay would seriously jeopardize health. IROs apply a medical-standard-of-care analysis that can override an insurer's off-label exclusion when evidence supports use.
• Request Humana's criteria: Humana must disclose the specific policy language and evidence standard applied. Request it in writing.

## Documentation to Gather

1. FDA clearance documentation — The 510(k) clearance letter or PMA approval for the device used, obtainable from the FDA's 510(k) database (accessdata.fda.gov) or the device manufacturer. 2. Dermatologist's medical-necessity and evidence letter — A letter from your treating physician explaining the FDA status, the clinical evidence base for efficacy in your indication, and references to AAD guidelines or peer-reviewed literature. 3. Humana's coverage policy — The exact policy language Humana applied, including any off-label use provisions and exception criteria. 4. Diagnosis and treatment history — Chart records confirming the acne diagnosis, severity, and the clinical decision-making that led to the specific procedure. 5. Peer-reviewed literature — Published studies supporting the procedure for your acne type or severity. Your dermatologist can identify the most relevant sources.

## Criteria-Mapping Structure

Address FDA status and medical-evidence separately in your appeal. For FDA status: confirm the device's clearance classification and indicate whether the specific indication is within the cleared scope. For medical evidence: list each criterion in Humana's "not FDA-approved" or investigational policy, then cite the published evidence or guideline that responds to it.